Endologix (NAS: ELGX) filed its 10-K on March 6. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Endologix met expectations on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly and GAAP earnings per share dropped to a loss.
Margins contracted across the board.
Endologix tallied revenue of $23.4 million. The six analysts polled by S&P Capital IQ wanted to see revenue of $23.5 million on the same basis. GAAP reported sales were 22% higher than the prior-year quarter's $19.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at -$0.06. The six earnings estimates compiled by S&P Capital IQ anticipated -$0.05 per share on the same basis. GAAP EPS were -$0.07 for Q4 against $0.22 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 76.9%, 110 basis points worse than the prior-year quarter. Operating margin was -14.0%, 1,660 basis points worse than the prior-year quarter. Net margin was -15.7%, 7,660 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $23.4 million. On the bottom line, the average EPS estimate is -$0.06.
Next year's average estimate for revenue is $105.2 million. The average EPS estimate is -$0.15.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 50 members out of 60 rating the stock outperform, and 10 members rating it underperform. Among 14 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 11 give Endologix a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Endologix is outperform, with an average price target of $13.50.
The health-care investing landscape is littered with also-rans and a few major winners. Is Endologix performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
Add Endologix to My Watchlist.
At the time thisarticle was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.